A Phase II Study of Imatinib Mesylate (STI571;NSC 716051;IND 61135) in Patients With Inoperable AJCC [American Joint Committee on Cancer] Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT.
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2014
At a glance
- Drugs Imatinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Sep 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.